Abstract
Anaemia is a common haematologic disorder in patients with cancer and has a multifactorial aetiology, including the effects of the malignancy itself and residual effects from previous therapy. Novel erythropoiesis stimulating protein (NESP, darbepoetin alfa), a protein with additional sialic acid compared with erythropoietin (EPO), stimulates erythropoiesis by the same mechanism as recombinant human erythropoietin (rHuEPO) but it is biochemically distinct. NESP, with its approximately 3-fold greater serum half-life, can maintain haemoglobin levels as effectively as rHuEPO in anaemic patients with chronic renal failure and do so with less frequent dosing. We investigated the ability of NESP to safely increase haemoglobin levels of anaemic patients with non-myeloid malignancies not receiving chemotherapy. NESP was administered under the supervision of a physician at doses of 0.5, 1.0, 2.25 or 4.5 mcg kg–1wk–1for a maximum of 12 weeks. This report includes 89 patients completing the study by November 2000. NESP was well tolerated, with no reported dose-limiting toxicities or treatment-related severe adverse events. Increasing doses of NESP corresponded with increased efficacy. The percentage (95% confidence interval) of patients responding ranged from 61% (42%, 77%) in the 1.0 mcg kg–1wk–1group to 83% (65%, 94%) in the 4.5 mcg kg–1wk–1group. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Abels RI, Larholt KM, Krantz KD, Bryant EC (1991) Recombinant human erythropoietin (r-HuEPO) for the treatment of anemia of cancer. In: Blood Cell Growth Factors: Their Present and Future use in Hematology and Oncology. Proceedings of the Beijing Symposium, Murphy MJ Jr (ed). AlphaMed Press: Dayton, OH 121–142
Cella D (1997) The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34: 13–19
Cooke K, Stoney G, Pistillo J, Del Castillo J, Molineux G and Coccia MA (2000) Anemia of chronic disease (ACD) in a rodent model is similar to human ACD and can be alleviated by ARANESP™ treatment. Blood 96: 8a (abstract 20)
Egrie JC, Dwyer E, Lykos M, Hitz A and Browne JK (1997) Novel erythropoiesis stimulating protein (NESP) has a longer serum half-life and greater in vivo biological activity than recombinant human erythropoietin (rHuEPO). Blood 90: 56a–57a (abstract 243)
Glaspy J, Colowick AB and Heatherington A (2000) Novel erythropoiesis stimulating protein (NESP) exhibits a prolonged serum half-life (T1/2) in oncology patients (pts). Proc Am Soc Clin Oncol 19: 54a (abstract 210)
Henry DH and Abels RI (1994) Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. Semin Oncol 21: 21–28
Jelkmann W (1998) Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res 18: 555–559
Ludwig H and Fritz E (1998) Anemia in cancer patients. Semin Oncol 25: 2–6
Ludwig H, Fritz E, Leitgeb C, Pecherstorfer M, Samonigg H and Schuster J (1994) Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 84: 1056–1063
Ludwig H, Sundal E, Pecherstorfer M, Leitgeb C, Bauernhofer T, Beinhauer A, Samonigg H, Kappeler AW and Fritz E (1995) Recombinant human erythropoietin for the correction of cancer associated anemia with and without cytotoxic chemotherapy. Cancer 76: 2319–2329
Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J and Egrie J (1999) Pharmacokinetics of novel erythropoiesis stimulating protein compared with Epoetin alfa in dialysis patients. J Am Soc Nephrol 10: 2392–2395
Miller CB, Jones RJ, Piantadosi S, Abeloff MD and Spivak JL (1990) Decreased erythropoietin response in patients with anemia of cancer. N Engl J Med 322: 1689–1692
Ozguroglu M, Arun B, Demir G, Demirelli F, Mandel NM, Buyukunal E, Serdengecti S and Berkarda B (2000) Serum erythropoietin level in anemic cancer patients. Med Oncol 17: 29–34
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Smith, R., Jaiyesimi, I., Meza, L. et al. Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer. Br J Cancer 84 (Suppl 1), 24–30 (2001). https://doi.org/10.1054/bjoc.2001.1749
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1749
Keywords
This article is cited by
-
Synthesis and Pharmacological Properties of the Azo-Conjugate of Erythropoietin β with Poly(Ethylene Glycol)
Pharmaceutical Chemistry Journal (2021)
-
Updates on Novel Erythropoiesis-Stimulating Agents: Clinical and Molecular Approach
Indian Journal of Hematology and Blood Transfusion (2020)
-
Analisi di minimizzazione dei costi degli agenti stimolanti l’eritropoiesi nel trattamento dell’anemia indotta da chemioterapia
PharmacoEconomics Italian Research Articles (2009)
-
Revisión sistemática de los estudios de calidad de vida de darbepoetina alfa en pacientes con anemia inducida por el tratamiento del cáncer
PharmacoEconomics Spanish Research Articles (2008)
-
Effect of Administering Recombinant Erythropoietin to Women with Postpartum Anemia: A Meta-analysis
Journal of Perinatology (2004)